METHYL ETHYL KETONE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 72.0 | 1.0 | 0 | 1 | 17.0 | 1 | 0.75 |
- CAS
- 78933
- UNII
- 6PT9KLV9IO
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 44 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT02225574 | 2015-03-01 | An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) | Phase 1/Phase 2 | Recruiting |
| NCT02049801 | 2014-12-01 | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting |
| NCT02089230 | 2014-08-01 | Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy | Phase 1/Phase 2 | Recruiting |
| NCT02105350 | 2014-06-01 | A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer | Phase 1 | Not Yet Recruiting |
| NCT02041481 | 2014-06-01 | MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer | Phase 1 | Recruiting |
| NCT01849874 | 2013-06-01 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Phase 3 | Recruiting |
| NCT01726738 | 2012-10-01 | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | Phase 2 | Recruiting |
| NCT01649336 | 2012-07-01 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | Phase 1 | Active, Not Recruiting |
| NCT01378377 | 2011-06-01 | Combination Trial MSC1936369B With Temsirolimus | Phase 1 | Completed |
| NCT01204177 | 2010-12-01 | Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. | Phase 2 | Completed |
| NCT01085331 | 2010-03-01 | MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) | Phase 1/Phase 2 | Completed |
| NCT01016483 | 2009-11-01 | Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | Phase 1/Phase 2 | Active, Not Recruiting |
| NCT00959127 | 2009-08-01 | A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer | Phase 1 | Completed |
| NCT00828165 | 2009-01-01 | A Safety Study of ARRY-300 in Healthy Subjects | Phase 1 | Completed |
| NCT00650767 | 2008-03-01 | A Study of ARRY-438162 in Patients With Rheumatoid Arthritis | Phase 2 | Completed |
| NCT00085787 | 2004-06-01 | A Study of ARRY-142886 in Patients With Advanced Cancer | Phase 1 | Completed |